Defining the proteomic landscape of rheumatoid arthritis: progress and prospective clinical applications

UDC.coleccionInvestigación
UDC.departamentoFisioterapia, Medicina e Ciencias Biomédicas
UDC.endPage444
UDC.grupoInvGrupo de Investigación en Reumatoloxía e Saúde (GIR-S)
UDC.grupoInvReumatoloxía (INIBIC)
UDC.institutoCentroCICA - Centro Interdisciplinar de Química e Bioloxía
UDC.institutoCentroINIBIC - Instituto de Investigacións Biomédicas de A Coruña
UDC.issue5
UDC.journalTitleExpert Review of Proteomics
UDC.startPage431
UDC.volume14
dc.contributor.authorLourido Salas, Lucía María
dc.contributor.authorBlanco García, Francisco J
dc.contributor.authorRuiz-Romero, Cristina
dc.date.accessioned2025-10-27T08:37:57Z
dc.date.available2025-10-27T08:37:57Z
dc.date.issued2017-05-02
dc.descriptionReview
dc.description.abstract[Abstract] The heterogeneity of Rheumatoid Arthritis (RA) and the absence of clinical tests accurate enough to identify the early stages of this disease have hampered its management. Therefore, proteomics research is increasingly focused on the discovery of novel biological markers, which would not only be able make an early diagnosis, but also to gain insight into the different pathological mechanisms underlying the heterogeneity of RA and also to stratify patients, which is critical to enabling effective treatments. Areas covered: The proteomic approaches that have been utilised to provide knowledge about RA pathogenesis, and to identify biomarkers for RA diagnosis, prognosis, disease monitoring and prediction of response to therapy, are summarized. Expert commentary: Although each proteomic study is unique in its design, all of them have contributed to the understanding of RA pathogenesis and the discovery of promising biomarkers for patient stratification, which would improve clinical care of RA patients. Still, efforts need to be made to validate these findings and translate them into clinical practice.
dc.description.sponsorshipThe authors were supported by grants from Fondo Investigación Sanitaria- Spain (PI16/02124, PI14/01707, CIBER-CB06/01/0040, RETIC-RIER-RD12/ 0009/0018). L. Lourido is funded by Xunta de Galicia (IN606B-2016/005), and C. Ruiz-Romero by the Miguel Servet II program from Fondo Investigación Sanitaria-Spain (CPII15/0013). The Proteomics Unit belongs to ProteoRed, PRB2-ISCIII, supported by grant PT13/0001.
dc.identifier.citationLourido L, Blanco FJ, Ruiz-Romero C. Defining the proteomic landscape of rheumatoid arthritis: progress and prospective clinical applications. Expert Rev Proteomics. 2017 May;14(5):431-444.
dc.identifier.doi10.1080/14789450.2017.1321481
dc.identifier.issn1478-9450
dc.identifier.urihttps://hdl.handle.net/2183/46100
dc.language.isoeng
dc.publisherTaylor & Francis
dc.relation.projectIDinfo:eu-repo/grantAgreement/MINECO//PI16%2F02124/ES/Determinación de índices predictivos de diagnóstico y pronóstico de artrosis de rodilla mediante la validación de biomarcadores proteicos/
dc.relation.projectIDinfo:eu-repo/grantAgreement/MINECO//PI14%2F01707/ES/Validación de biomarcadores proteicos de artrosis mediante proteómica dirigida para el desarrollo de un método de diagnóstico in vitro/
dc.relation.urihttps://doi.org/10.1080/14789450.2017.1321481
dc.rightsThis is an Accepted Manuscript of an article published by Taylor & Francis in Expert Review of Proteomics on 2017, available at Taylor & Francis Online
dc.rights.accessRightsopen access
dc.subjectBiomarkers
dc.subjectPathogenesis
dc.subjectPatient stratification
dc.subjectProteomics
dc.subjectRheumatoid arthritis
dc.titleDefining the proteomic landscape of rheumatoid arthritis: progress and prospective clinical applications
dc.typejournal article
dc.type.hasVersionAM
dspace.entity.typePublication
relation.isAuthorOfPublicationf357279a-035a-4279-a553-99cfd79bd2bb
relation.isAuthorOfPublication.latestForDiscoveryf357279a-035a-4279-a553-99cfd79bd2bb

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Lourido_Defining_2017.pdf
Size:
365.28 KB
Format:
Adobe Portable Document Format